Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:

• the light chain variable region (VL) polypeptide having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO:
• 39 and SEQ ID NO:
• 40;
• and
• the heavy chain variable region (VH) having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO:
• 48, SEQ ID NO:
• 49, SEQ ID NO:
• 50 and SEQ ID NO:
• 51.

A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:

• the light chain variable region (VL) polypeptide having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO:
• 34, SEQ ID NO:
• 35, SEQ ID NO:
• 36, SEQ ID NO:
• 37, SEQ ID NO:
• 38, SEQ ID NO:39 and SEQ ID NO:
• 40, and
• the heavy chain variable region (VH) having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO:
• 41, SEQ ID NO:
• 42, SEQ ID NO:
• 43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:
• 47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50 and SEQ ID NO:
• 51.

A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:

• a) a light chain variable region (VL) polypeptide having the amino acid sequence SEQ ID NO:
• 14;
• and
• b) a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO:
• 15.